Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
NCT05624268 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 255
Last updated 2025-12-18
Summary
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Conditions
Interventions
- DRUG
-
COMP360 Psilocybin administered under supportive conditions
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-19
- Primary Completion
- 2025-05-28
- Completion
- 2026-04-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Psilocybin for Treatment-Resistant Depression
NCT05029466 ·Status: COMPLETED ·Phase: PHASE2
-
Psilocybin for Treatment-Resistant Depression
NCT06230757 ·Status: COMPLETED ·Phase: PHASE2
-
Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression
NCT07183748 ·Status: RECRUITING ·Phase: PHASE2
-
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
NCT04433858 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
NCT06341426 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
NCT04670081 ·Status: COMPLETED ·Phase: PHASE2
-
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
NCT06303739 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Psilocybin for Hospitalized Patients with Treatment-resistant Depression
NCT06378229 ·Status: RECRUITING ·Phase: PHASE2
-
Psilocybin for Major Depressive Disorder
NCT05675800 ·Status: WITHDRAWN ·Phase: PHASE2
-
Psilocybin for Major Depressive Disorder (MDD)
NCT06308653 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
NCT06247839 ·Status: RECRUITING ·Phase: PHASE3
-
Psilocybin for Treatment-Resistant Depression in Autism
NCT06731621 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression
NCT07211438 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
NCT07226232 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
NCT05381974 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Psilocybin for Major Depressive Disorder (MDD)
NCT03866174 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
NCT00621270 ·Status: COMPLETED ·Phase: PHASE2
-
PET Synaptogenesis After Psilocybin In DEpression Recovery
NCT05601648 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
NCT04630964 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Psilocybin in Major Depressive Disorder
NCT03181529 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept
NCT03715127 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
NCT06570369 ·Status: RECRUITING ·Phase: PHASE1
-
A Trial of GH001 in Patients With Treatment-resistant Depression
NCT05800860 ·Status: COMPLETED ·Phase: PHASE2
-
AZD6765 for Treatment Resistant Depression
NCT00491686 ·Status: COMPLETED ·Phase: PHASE2